We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A UK-based consortium of companies is developing an implantable microgenerator to convert energy from human body movement, including joint movement and heartbeats, into power for implanted medical devices such as pacemakers, electrical stimulators and instrumented joints.
The Society for Cardiovascular Angiography and Interventions (SCAI), an international group representing invasive and interventional cardiologists, released a clinical alert Jan. 11 advising physicians on the steps they can take to reduce the risk of late thrombosis, or clotting, from the use of drug-eluting stents.
The recently announced reallocation by Boston Scientific of its cardiac rhythm management (CRM) research and development resources should not affect earnings, an analyst says.
Nassif Associates received a recent FDA warning letter for current good manufacturing practice violations regarding the company's cardio-card interpretation systems.
A blood test for coronary heart disease could help predict which patients are at higher risk than others for adverse cardiovascular events or death, according to a study published in the Jan. 10 issue of The Journal of the American Medical Association.
In a final rule published in the Jan. 10 Federal Register, the FDA has classified quality control material for cystic fibrosis nucleic acid assays into Class II, or special controls. The agency also published related guidance.
A Swiss study published Jan. 2 in the Journal of the American College of Cardiology found that "collateral function" -- the functioning of small collateral heart vessels -- is more severely impaired in patients implanted with drug-eluting stents than in those implanted with bare-metal stents six months after implantation.
The FDA has recommended Advanced Medical Optics (AMO) enroll additional subjects in its U.S. clinical study for the Tecnis Multifocal intraocular lens (IOL), setting back the scheduled entry of the device into the U.S. market.
When designing medical devices that use radio-frequency (RF) wireless technology, firms should consider how those products will interact with other devices and respond to potential electromagnetic interference, the FDA says in new draft guidance.